Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Obalon Therapeutics Inc (OBLN)

Obalon Therapeutics Inc (OBLN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Obalon To Present at Two Upcoming Institutional Investor Conferences

Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon...

OBLN : 1.78 (-1.11%)
OBALON THERPTCS (OBLN) Reports Q3 Loss, Misses Revenue Estimates

OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 82.57% and -84.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

OBLN : 1.78 (-1.11%)
Obalon Announces Third Quarter 2019 Financial Results

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced...

OBLN : 1.78 (-1.11%)
Obalon Announces Clinical Data Set to be Featured During the 36th ASMBS Annual Meeting at Obesity Week 2019

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces...

OBLN : 1.78 (-1.11%)
OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OBLN : 1.78 (-1.11%)
Obalon Schedules Third Quarter 2019 Financial Results Conference Call for November 8, 2019 at 9:00 a.m. Eastern Time

Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces...

OBLN : 1.78 (-1.11%)
Will OBALON THERPTCS (OBLN) Report Negative Q3 Earnings? What You Should Know

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OBLN : 1.78 (-1.11%)
Obalon Appoints William J. Plovanic as Chief Executive Officer and Nooshin Hussainy as Chief Financial Officer

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric...

OBLN : 1.78 (-1.11%)
Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss, announces it has...

OBLN : 1.78 (-1.11%)
Obalon Announces Repayment of All Long-Term Debt and Regaining of Compliance with NASDAQ Listing Requirement

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for...

OBLN : 1.78 (-1.11%)
Obalon (OBLN) Alert: Johnson Fistel Announces Shareholder Class Action Against Obalon Therapeutics Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses?

Johnson Fistel, LLP is investigating potential claims on behalf of Obalon Therapeutics, Inc. (NASDAQ: OBLN) ("Obalon" or the "Company") against certain of its officers and directors.

OBLN : 1.78 (-1.11%)
Obalon Engages Helmuth T. Billy, MD as Medical Director for its First Company-Owned Weight Loss Treatment Center

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for...

OBLN : 1.78 (-1.11%)
Obalon Therapeutics Inc. Announces Closing of $16.6 Million Public Offering

Obalon Therapeutics Inc. (Nasdaq: OBLN) (the "Company"), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for...

OBLN : 1.78 (-1.11%)
Obalon Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of...

OBLN : 1.78 (-1.11%)
Obalon Therapeutics Inc. Announces Pricing of $15,000,000 Public Offering

Obalon Therapeutics Inc. (Nasdaq: OBLN) (the "Company"), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for...

OBLN : 1.78 (-1.11%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Obalon Therapeutics, Inc. - OBLN

Levi & Korsinsky announces it has commenced an investigation of Obalon Therapeutics, Inc. (NASDAQ: OBLN) concerning possible breaches of fiduciary duty. To obtain additional information, go to:

OBLN : 1.78 (-1.11%)
OBALON THERPTCS (OBLN) Reports Q2 Loss, Misses Revenue Estimates

OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 7.41% and -78.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

OBLN : 1.78 (-1.11%)
Obalon Announces Reverse Stock Split Effective Today

Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of...

OBLN : 1.78 (-1.11%)
Obalon Announces Second Quarter 2019 Financial Results

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of...

OBLN : 1.78 (-1.11%)
Obalon Enters Into Commercial Lease for its First Company-Owned Retail Weight Loss Center

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of...

OBLN : 1.78 (-1.11%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -3.13 , AIZ +0.16 , SBAC -5.36 , SO +0.21 , WELL +0.15
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar